Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Titus, M. A.
Right arrow Articles by Mohler, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Titus, M. A.
Right arrow Articles by Mohler, J. L.
Clinical Cancer Research Vol. 11, 4365-4371, June 15, 2005
© 2005 American Association for Cancer Research

Imaging, Diagnosis, Prognosis

Steroid 5{alpha}-Reductase Isozymes I and II in Recurrent Prostate Cancer

Mark A. Titus4, Christopher W. Gregory1,4, O. Harris Ford, III4, Michael J. Schell3,4, Susan J. Maygarden1 and James L. Mohler1,2,4,5,6

Authors' Affiliations: Departments of 1 Pathology and Laboratory Medicine, 2 Surgery, 3 Biostatistics, and 4 UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, 5 Department of Urologic Oncology, Roswell Park Cancer Institute, and 6 Department of Urology, University at Buffalo School of Medicine and Biotechnology, Buffalo, New York

Requests for reprints: Mark A. Titus, UNC Lineberger Comprehensive Cancer Center, CB#7295, University of North Carolina, Chapel Hill, NC 27599-7295. Phone: 919-966-9257; Fax: 919-966-3015; E-mail: matitus{at}med.unc.edu.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Prostate cancer recurs during androgen deprivation therapy despite reduced circulating androgens. We showed that recurrent prostate cancer tissue has testosterone levels similar to androgen-stimulated benign prostate, whereas dihydrotestosterone levels were reduced 82% to 1.45 nmol/L, sufficient for androgen receptor activation. The altered testosterone/dihydrotestosterone ratio in recurrent prostate cancer suggests loss of 5{alpha}-reducing capability. The aim of this study was to characterize steroid 5{alpha}-reductase isozymes I (S5{alpha}RI) and II (S5{alpha}RII) in prostate tissues.

Experimental Design: A tissue microarray was constructed from 22 recurrent prostate cancer specimens and matched pairs of androgen-stimulated benign prostate and androgen-stimulated prostate cancer from 23 radical prostatectomy specimens. Immunoblots were constructed from eight recurrent prostate cancers, eight androgen-stimulated benign prostate, and eight androgen-stimulated prostate cancer specimens. Isozyme expression was examined in microarray sections and immunoblots using S5{alpha}RI and S5{alpha}RII polyclonal antibodies. Isozyme activities were measured in 12 recurrent prostate cancer, 12 androgen-stimulated benign prostate, and 12 androgen-stimulated prostate cancer specimens.

Results: Nuclear immunostaining exhibited higher S5{alpha}RI expression than S5{alpha}RII in recurrent prostate cancer, androgen-stimulated benign prostate, and androgen-stimulated prostate cancers (P < 0.0001); mean expression was 125, 150, and 115 for S5{alpha}RI versus 10, 29, and 37 for S5{alpha}RII, respectively. Cytoplasmic immunostaining was moderate and similar for both isozymes in the three tissue types (P > 0.05). Immunoblots confirmed immunohistochemistry; S5{alpha}RI was expressed in recurrent prostate cancer specimens and S5{alpha}RII was not detected. The activity of S5{alpha}RI (114.4 pmol/mg epithelial protein/minute) was 3.7-fold higher than S5{alpha}RII (30.7 pmol/mg epithelial protein/minute) in recurrent prostate cancer specimens.

Conclusions: Expression levels and isozyme activity shifts from S5{alpha}RII toward S5{alpha}RI in recurrent prostate cancer. Dual inhibition of S5{alpha}RI and S5{alpha}RII should reduce dihydrotestosterone biosynthesis and may prevent or delay growth of recurrent prostate cancer.

Key Words: recurrent prostate cancer • dihydrotestosterone • steroid 5{alpha}-reductase isozyme I and II • immunohistochemistry • metabolomics

Androgen target cells in peripheral tissues use testosterone to activate androgen receptor, which interacts with androgen response elements in DNA to regulate gene transcription. Alternatively, intracellular testosterone acts as a prohormone that is converted to dihydrotestosterone, a more potent androgen receptor ligand. In the prostate, an intracrine pathway (1) uses the enzyme steroid 5{alpha}-reductase (EC 1.3.99.5) to metabolize testosterone to dihydrotestosterone. The adrenal androgen androstenedione is also converted to 5{alpha}-reduced androstanedione by steroid 5{alpha}-reductase in the prostate (2) and androstenedione has been implicated as a source of dihydrotestosterone in prostate tissue after castration (3).

Steroid 5{alpha}-reductase is a membrane-associated, NADPH-dependent enzyme that catalyzes the irreversible stereospecific reduction of C19 3-keto-{Delta}4-5 steroid to 5{alpha}-reduced metabolites. Steroid 5{alpha}-reductase isozymes I (S5{alpha}RI) and II (S5{alpha}RII) in humans are composed of 260 and 254 amino acids, respectively, with 47% sequence identity and distinct biochemical properties (4). S5{alpha}RI exhibits a broad neutral to basic optimum pH range, whereas S5{alpha}RII displays a narrow acid pH optimum for maximum activity. Both isozymes contain an NH2-terminal steroid binding domain and a COOH-terminal NADPH binding domain. S5{alpha}RI has higher turnover and decreased substrate affinity, whereas S5{alpha}RII has lower turnover and increased substrate affinity. The apparent dissociation constant for NADPH cofactor is similar for both isozymes.

Prostate cancer is the second leading cause of death and the most common non–skin cancer in American men. Current estimates predict 232,090 new cases of prostate cancer in American men and 30,350 deaths from prostate cancer in 2004 (5). Men who fail curative therapy or present with advanced disease usually receive androgen deprivation therapy that causes regression of androgen-dependent prostate cancer through programmed cell death (6). However, androgen deprivation therapy is palliative in advanced prostate cancer (7) because prostate cancer recurs and almost always causes death. A molecular role for androgen receptor in the transition from androgen-stimulated prostate cancer to recurrent prostate cancer is supported by androgen receptor expression in recurrent prostate cancer (8–10) and expression of androgen-regulated genes (10–12). Potential mechanisms include androgen receptor amplification (13), androgen receptor gene mutations leading to transactivation by low levels of dihydrotestosterone (14) or promiscuous ligand binding (15) and posttranslational modification of androgen receptor through peptide growth factor signaling (16, 17). In addition to these mechanisms, our investigations have recently found tissue levels of testosterone and dihydrotestosterone in recurrent prostate cancer that are sufficient for activation of even wild-type androgen receptor (10). However, lack of efficacy of finasteride, a S5{alpha}RII-specific inhibitor, suggests that S5{alpha}RII does not contribute significantly to dihydrotestosterone production (18).

We investigated the expression levels, subcellular location and in vitro enzymatic activity of S5{alpha}R isozymes I and II in recurrent prostate cancer compared with androgen-stimulated benign prostate and androgen-stimulated prostate cancer. S5{alpha}RI and II expression were characterized using tissue microarray immunohistochemistry and Western analysis, and enzymatic activity was assessed using pH-optimized assays for each isozyme.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Patient and tissue samples. All prostate specimens were acquired in compliance with the guidelines of the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Clinical Protocol Review Committee and Institutional Review Board and the federal Health Insurance Portability and Accountability Act protected health information regulations. Immediately after surgical removal, tissue specimens were formalin-fixed and paraffin-embedded or placed in cryovials, snap-frozen in liquid nitrogen, and cryopreserved until further processing. All histologic diagnoses were confirmed by examination of frozen and corresponding formalin-fixed, paraffin-embedded tissue specimens. Prostate specimens from a total of 105 men were used for tissue microarray immunohistochemistry (n = 45), immunoblot analysis (n = 24), and enzyme assays (n = 36).

A tissue microarray was constructed that contains a total of 68 cores from a total of 45 men. Androgen-stimulated benign prostate and prostate cancer cores were obtained from the transition zone of formalin-fixed, paraffin-embedded radical prostatectomy specimens from 23 men with clinically localized prostate cancer. The patients had not received radiation or hormonal therapy prior to surgery. Mean age was 57 years (range 46-73) and Gleason sums ranged from 5 to 8. Recurrent prostate cancer cores were obtained from formalin-fixed, paraffin-embedded transurethral prostatectomy specimens from 22 men who had increasing serum prostate-specific antigen levels and urinary retention from local recurrence of prostate cancer after surgical or medical androgen deprivation therapy. Mean age was 72 years (range 57-86) and Gleason sums ranged from 8 to 10.

Steroid 5{alpha}-reductase enzyme assays were performed using snap-frozen operative specimens from 36 men, the samples were then stored in liquid nitrogen until further use. Twelve samples of androgen-stimulated benign prostate, 12 samples of androgen-stimulated prostate cancer, and 12 samples of recurrent prostate cancer were sources of steroid enzymes. The patients with androgen-stimulated benign prostate had a mean age of 63 years (range 50-75). Patients with androgen-stimulated prostate cancer had a mean age of 54 years (range 39-76) and Gleason sums were 6 or 7. Patients with recurrent prostate cancer had a mean age of 71 years (range 60-86) and Gleason sums ranged from 8 to 10.

An immunoblot was constructed from frozen prostate tissue specimen lysates from 24 different men (19) that yielded eight samples each of androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer. The androgen-stimulated benign prostate patients had a mean age of 65 years (range 58-71). Androgen-stimulated prostate cancer patients had a mean age of 59 years (range 41-71) and Gleason sums were 6 or 7. Recurrent prostate cancer patients had a mean age of 71 years (range 60-86) and Gleason sums ranged from 8 to 10.

Microarray construction. A high-density tissue microarray was constructed using formalin-fixed, paraffin-embedded human prostate specimens as previously described (20). The tissue microarrays were constructed with matched pairs of androgen-stimulated benign prostate and prostate cancer from radical prostatectomy specimens from 23 men and recurrent prostate cancer from transurethral resection specimens from 22 men using the Beecher Instruments (Silver Spring, MD) manual tissue arrayer. Benign prostate obtained by transurethral resection, colon cancer, and mouse liver cores were included as internal controls for standardization.

Six-micrometer sections were cut from donor paraffin blocks and stained with H&E using routine methods. A pathologist (S.J. Maygarden) evaluated the tissue sections and identified benign prostate and prostate cancer. The regions of interest were sampled by removing a 1.5 mm tissue core. These cores were implanted into a recipient paraffin block to create an array containing a total of 84 tissue cores that includes 22 cores of recurrent prostate cancer, 23 cores of androgen-stimulated benign prostate, 23 cores of androgen-stimulated prostate cancer, and 16 duplicate and control tissues.

Immunohistochemistry. Optimal conditions were defined for immunodetection of 5{alpha}-reductase isozymes (21). Tissue microarray immunohistochemistry was done using the tape-transfer method of tissue mounting (Instrumedics; Hoboken, NJ) and the EnVision + Peroxidase System (Dako Cytomation; Carpinteria, CA). Six-micrometer sections of formalin-fixed, paraffin-embedded specimens were deparaffinized and rehydrated using Hemo-De and graded alcohols. Antigens were retrieved by incubation in citrate buffer (pH 6.0; Biocare Medical, Walnut Creek, CA) for 2 minutes at 120°C and 22 psi. Endogenous peroxidases were blocked using 0.03% H2O2 for 5 minutes at 37°C. Specimens were incubated for 30 minutes at 37°C with anti-human S5{alpha}RI (12 µg/mL) and S5{alpha}RII (6 µg/mL) IgG specific for NH2-terminal epitopes (21). Tissues were incubated with polymer-conjugated anti-rabbit IgG (Dako Cytomation) followed by visualization using diaminobenzidine tetrahydrochloride (Vector Labs, Burlingame, CA). Counterstaining was done using hematoxylin (Gill's formula, Vector Labs). Specificity was confirmed when S5{alpha}RI and S5{alpha}RII polyclonal antibody binding to antigen was prevented by preincubation with S5{alpha}RI or S5{alpha}RII epitope peptide (22).

Quantitative morphometry. Tissue sections from 36 prostate specimens were cut at 6 µm, deparaffinized, and stained with H&E. An average of 12 images per patient specimen were collected and analyzed using Image Pro Plus 4.5 (Media Cybernetics, Inc. Silver Spring, MD). Each visible lumen was circled and the enclosed area calculated. Epithelium was circled and the area calculated by subtracting the area of the lumen. The area of the stroma was determined by subtracting the area of the lumen and epithelium from total image size. Percent epithelium was the area of the epithelium divided by the sum of the area of the epithelium and the area of the stroma. Percent stroma was the area of stroma divided by the sum of the area of epithelium and the area of stoma (23).

Image acquisition analysis. One or two random images were acquired at 400x magnification from each core on the tissue microarray using Leica DMRA2 microscope (Leica Microsystems, Inc., Bannockburn, IL) with a Ludl stage controller (Ludl Electronic Products, Ltd., Hawthorne, NY) and a Hamamatsu 3 Chip CCD camera with controller (Hamamatsu, Bridgewater, NJ) interfaced with a Flashpoint three-dimensional image grabber card (Integral Technologies, Indianapolis, IN) in a Pentium IV-based PC. Image Pro Plus 4.5 (Media Cybernetics) software was used to capture and store the images. The images have 24-bit color depth and 640 x 480 pixel resolution and were stored as TIFF image files. An image album was created using Adobe Photoshop 7.0 (Adobe Systems, Inc., San Jose, CA) with the acquired images for visual scoring.

Tissue microarray sections were visually scored by experienced observers (M.A. Titus and O.H. Ford) blinded to type of antibody and the androgen status of the patients from whom tissue was procured. In addition, O.H. Ford was blinded to the nature of the experiment. Epithelial nuclear and cytoplasmic S5{alpha}RI and S5{alpha}RII immunostaining were semiquantitatively assessed on a scale ranging from 0 (no expression) to 3 (strong immunostaining) in each of 100 nuclei or cells, respectively, to yield a visual score ranging from 0 to 300 for each feature for each specimen (24).

Statistical analysis. Data were described by the mean visual scores of S5{alpha}RI and S5{alpha}RII immunostaining. Statistical analyses were done using Statgraphics Plus 4.1 (Manugistics, Inc., Rockville, MD). Student's t test was used to compare S5{alpha}-RI and II nuclear immunostaining in androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer, followed by ANOVA (Tukey HSD multiple comparison test). Differences were considered significant at P < 0.05.

Steroid 5{alpha}-reductase in vitro assays. Tissue preparation and enzyme incubations protocols by Moore and Wilson (25) were used with modifications. All steps were carried out at 4°C. Fifty milligrams of prostate tissue were used to allow sufficient protein concentrations for multiple assays. The total protein concentration of each of 12 samples of androgen-stimulated benign prostate, 12 samples of androgen-stimulated prostate cancer, and 12 samples of recurrent prostate cancer was converted to epithelial protein concentration by dividing total protein concentration by percent epithelium. S5{alpha}RI and S5{alpha}RII specific activities were expressed in picomoles per milligram of epithelial protein per minute for each specimen.

Prostate tissue was pulverized in liquid nitrogen using mortar and pestle and homogenized in 1 mL ice-cold homogenization buffer [10 mmol/L Tris-HCl (pH 7.4), 0.25 mol/L sucrose, 1 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L fresh phenylmethylsulfonyl chloride, 1.3x Halt protease inhibitor (Pierce, Rockford, IL), 3 mmol/L NADPH (Roche Applied Science Indianapolis, IN), and 0.5 nmol/L androstenedione (Sigma-Aldrich, St. Louis, MO)] using a PowerGen 700 for three 10-second bursts. Final homogenates were centrifuged at 800 x g for 5 minutes to remove connective tissue. The resulting cell-free supernatants were stored in 250 µL aliquots at –80°C. Protein concentrations were measured using the procedure of Lowry et al. (26).

The buffer for all incubations contained 150 mmol/L Tris-citrate, 0.5 mmol/L DTT, 0.5 mmol/L EDTA, 0.5 mmol/L fresh phenylmethylsulfonyl chloride, 0.25 mg/mL bovine serum albumin, 3 mmol/L NADPH, and 50 nmol/L [3H]androstenedione (New England Nuclear, Boston, MA). Incubations were done in a total volume of 200 µL at pH 7.5 for S5{alpha}RI and pH 5.5 for S5{alpha}RII. Enzymatic reaction was initiated by the addition of 50 µL supernatant that was mixed gently for 5 seconds and shaken for 30 minutes in a 37°C water bath. The incubations were quenched by adding of 1 mL ice-cold chloroform/methanol (8:2, vol/vol) that was vortexed vigorously and placed on ice after centrifugation to separate organic and water phases. Homogenization buffer at 0.9% ethanol was added to control incubations in place of cell-free supernatant. All incubations were done in duplicate under protein and time linearity.

The conversion of androstenedione to 5{alpha}-reduced metabolites androstanedione and dihydrotestosterone was measured using TLC (25, 27). An aliquot of dissolved organic extraction containing tritiated steroids and internal standards (0.25 mg/mL dihydrotestosterone, androstenedione, androstanedione, testosterone; Sigma-Aldrich) were separated using silica-coated flexible plates and chloroform/methanol (98:2, vol/vol) mobile phase. The developed plates were visualized using anisaldehyde spray. Zones corresponding to stained reference steroids were transferred into vials containing 5 mL of liquid scintillation cocktail and assayed for tritium. Control incubations lacking enzyme were analyzed as described above.

The relative amount of each radioactive steroid was calculated as percent total radioactivity (3H) recovered from the TLC lane. Blank values were subtracted from tissue metabolism rates.

Immunoblot analysis. Protein lysates from frozen patient samples were isolated as described previously (19). Briefly, 100 mg tissue pieces were pulverized under liquid nitrogen and mixed with 1 mL of radioimmunoprecipitation buffer containing protease inhibitors [0.15 mol/L NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mmol/L EDTA, 50 mmol/L Tris (pH 7.4), 0.5 mmol/L phenylmethylsulfonyl fluoride, 10 µmol/L pepstatin, 4 µmol/L aprotinin, 80 mg/mL leupeptin, 0.2 mmol/L sodium vanadate, and 5 mmol/L benzamidine] and 1 µmol/L dihydrotestosterone. After homogenization and incubation for 15 minutes on ice, lysates were centrifuged at 12,000 x g twice for 15 minutes. Supernatant proteins (100 µg) were electrophoresed on 10% polyacrylamide gels containing SDS and electroblotted to Immobilon-P membranes (Millipore Corp., Bedford, MA). Immunoblot analysis was done using S5{alpha}RI and S5{alpha}RI antibodies (1.0 µg/mL) and horseradish peroxidase conjugated rabbit IgG. Specific signals were detected using enhanced chemiluminescence (SuperSignal West Dura Extended Duration Substrate, Pierce).


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Nuclear S5{alpha}RI immunostaining was moderate and similar in androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer (Table 1; Fig. 1). Epithelial nuclei exhibited lower S5{alpha}RII than S5{alpha}RI immunostaining in androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer (P < 0.0001). The difference between S5{alpha}RI and S5{alpha}RII nuclear immunostaining varied marginally across the three tissue types (ANOVA, P = 0.055). Nuclear S5{alpha}RII immunostaining in recurrent prostate cancer was lower than androgen-stimulated benign prostate and androgen-stimulated prostate cancer (P < 0.0001). Cytoplasmic S5{alpha}RI immunostaining was lower in recurrent prostate cancer than androgen-stimulated benign prostate or androgen-stimulated prostate cancer (P < 0.00001). Recurrent prostate cancer cytoplasmic S5{alpha}RII had decreased immunostaining versus androgen-stimulated benign prostate or androgen-stimulated prostate cancer (P < 0.0001). S5{alpha}RI and S5{alpha}RII immunostaining was not detectable in androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer stroma.


View this table:
[in this window]
[in a new window]
  		Table 1. Nuclear and cytoplasmic visual scores of S5{alpha}RI/II immunostaining in tissue microarray of androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer

 


View larger version (85K):
[in this window]
[in a new window]
  		Fig. 1. Photomicrographs of S5{alpha}RI and S5{alpha}RII expression in a tissue microarray containing androgen-stimulated benign prostate (AS-BP), androgen-stimulated prostate cancer (AS-CaP) and recurrent prostate cancer. Original magnification, x400.

 
Immunoblot analysis confirmed immunohistochemical results. In recurrent prostate cancer, the 23 kDa S5{alpha}RI was expressed at high levels in six specimens and intermediate levels in two specimens (Fig. 2). S5{alpha}RII expression was below detectable levels in all eight recurrent prostate cancer specimens even after extended exposure. Expression levels of S5{alpha}RI and S5{alpha}RII were similar across all eight androgen-stimulated benign prostate specimens. The eight androgen-stimulated prostate cancer specimens revealed variable levels of expression of S5{alpha}RI and S5{alpha}RII. All three tissue types, androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer, showed greater expression of S5{alpha}RI than S5{alpha}RII.



View larger version (77K):
[in this window]
[in a new window]
  		Fig. 2. Immunoblot analysis of S5{alpha}RI and S5{alpha}RII in human prostate tissues. Immunoblotting was done using purified S5{alpha}RI and S5{alpha}RII polyclonal antibodies and lysates from (A) androgen-stimulated benign prostate, (B) androgen-stimulated prostate cancer, and (C) recurrent prostate cancer specimens. Molecular weight standard proteins are indicated in kilodaltons (kDa).

 
The proportion of the 5{alpha}-reducing capability determined under optimal conditions varied in the three tissue types. Epithelium comprised a median of 25% in androgen-stimulated benign prostate, 52.7% in androgen-stimulated prostate cancer, and 94.8% in recurrent prostate cancer (Table 2). In both androgen-stimulated benign prostate and androgen-stimulated prostate cancer, S5{alpha}RII activity exceeded S5{alpha}RI activity (Table 3). However, in recurrent prostate cancer, S5{alpha}RI activity was 3.7-fold greater than S5{alpha}RII activity.


View this table:
[in this window]
[in a new window]
  		Table 2. Median and average percent epithelium and stroma in 36 patient specimens used for enzymatic analyses

 

View this table:
[in this window]
[in a new window]
  		Table 3. The median and range of steroid 5{alpha}-reductase activity at acidic and neutral pH (pmol/mg epithelial protein/min) shows 5{alpha}-reductase reducing capability shifts to isozyme I in recurrent prostate cancer

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
S5{alpha}RI and S5{alpha}RII immunostaining was detected in nuclear and cytoplasmic compartments of androgen-stimulated benign prostate, androgen-stimulated prostate cancer, and recurrent prostate cancer epithelial cells but no immunostaining was detected in stroma. In recurrent prostate cancer, S5{alpha}RI localized predominantly to the nucleus and S5{alpha}RII localized predominantly to the cytoplasm. The subcellular nuclear localization of S5{alpha}RI and cytoplasmic localization of S5{alpha}RII in recurrent prostate cancer epithelium shown in this study has been reported previously in normal prostate tissue (28). Bonkhoff et al. (29) characterized S5{alpha}RI and S5{alpha}RII immunoreactivity in benign prostate tissue and recurrent prostate cancer. S5{alpha}RI and S5{alpha}RII showed increased nuclear and cytoplasmic immunostaining in recurrent prostate cancer, respectively, compared with benign prostate (29). In this study, S5{alpha}RI nuclear immunostaining remained similar between androgen-stimulated benign prostate and recurrent prostate cancer and cytoplasmic S5{alpha}RII was significantly lower in recurrent prostate cancer. The ratio of S5{alpha}RI/S5{alpha}RII immunostaining changed from approximately 5:1 in androgen-stimulated benign prostate and 3:1 in androgen-stimulated prostate cancer to 12:1 in recurrent prostate cancer. The COOH-terminal specific S5{alpha}RI and S5{alpha}RII antibodies and extended antibody exposure time used in the previous study may explain the differences in the two studies. Our immunohistochemistry data was supported further by Western blots and enzyme assays.

5{alpha}-Reductase activity in human hyperplastic and malignant tissues has been reported previously (30). More recently, individual isozyme activities have been shown in specimens of benign hyperplasia (31) and prostate cancer (32). Our results for androgen-stimulated benign prostate and androgen-stimulated prostate cancer agree with S5{alpha}RI and S5{alpha}RII activities reported previously by Soderstrom et al. (32). To our knowledge, individual S5{alpha}RI and S5{alpha}RII isozyme activities have not been reported in recurrent prostate cancer. S5{alpha}RI activity is 3.7-fold that of S5{alpha}RII in recurrent prostate cancer. The increased S5{alpha}RI enzyme activity is consistent with higher levels of S5{alpha}RI enzyme found by immunohistochemistry and immunoblot. The residual S5{alpha}RII enzyme activity in recurrent prostate cancer tissue may be attributed to S5{alpha}RI activity (33) which persists at optimal pH in this in vitro system.

The switch toward S5{alpha}RI expression in recurrent prostate cancer may be in response to angiogenesis (34) and its role in epithelial microenvironment regulation. Neovascularization mediated by vascular endothelial growth factor, a universal characteristic of solid tumors, has been linked to aggressiveness of prostate cancer (35). Androgens regulate vascular endothelial growth factor production in prostate cancer (36). Although angiogenesis increases tumor vascularization, portions of the tumor and even cells adjacent to neovessels may be hypoxic (37). A hypoxic microenvironment stabilizes hypoxia-inducible factor 1{alpha} and changes tumor metabolism by increasing expression of hypoxia-inducible factor 1{alpha} target genes. One such protein, carbonic anhydrase 9 (38), is a tumor-associated transmembrane enzyme that may influence microenvironmental pH. Additionally, the promoter of carbonic anhydrase 9 has been reported to be sensitive to increased cell density (39) that is characteristic of recurrent prostate cancer. Wykoff et al. (38) proposed carbonic anhydrase 9 expression provides a mechanism for maintaining extracellular acidosis and intracellular alkalosis (40) which promotes tumor growth. The intracellular basic pH would serve to optimize S5{alpha}RI activity in recurrent prostate cancer. The S5{alpha}RI dihydrotestosterone production in turn stimulates tumor growth and hypoxia-inducible factor 1{alpha} expression, which promotes tumor growth and basic intracellular pH. The hypoxic tissue microenvironment favors S5{alpha}RI conversion of testosterone to dihydrotestosterone and stabilizes hypoxia-inducible factor 1{alpha} transcription factor which in turn increases expression of its target genes.

The kinetic variables of S5{alpha}RI are distinct from S5{alpha}RII (41). S5{alpha}RI requires higher steroid substrate concentration compared with S5{alpha}RII to achieve half maximal rate of dihydrotestosterone production. In androgen-stimulated prostate, both isozymes contribute to dihydrotestosterone production, but loss of S5{alpha}RII activity decreases the amount of dihydrotestosterone formed in recurrent prostate cancer. Secondly, testosterone levels should be elevated because the S5{alpha}RI dissociation constant is increased requiring higher testosterone levels to drive S5{alpha}RI conversion of testosterone to dihydrotestosterone. Therefore, recurrent prostate cancer testosterone levels should be elevated because of minimal S5{alpha}RII expression and increased S5{alpha}RI substrate dissociation constant. Furthermore, recurrent prostate cancer dihydrotestosterone levels should decrease due to loss of both S5{alpha}RII and S5{alpha}RI expression in recurrent prostate cancer. These factors support the equivalent testosterone levels detected in androgen-stimulated benign prostate and recurrent prostate cancer specimens and decreased dihydrotestosterone levels in recurrent prostate cancer compared with androgen-stimulated benign prostate (10).

The relatively high testosterone level found in recurrent prostate cancer could also result in local estradiol biosynthesis by cytochrome P450 aromatase (EC 1.14.14.1, Fig. 3). Aromatase protein and activity has been shown in prostate cancer (42) and adipose tissue in men during aging (43). Estradiol biosynthesis may increase peripherally in adipose tissue or locally in recurrent prostate cancer as a consequence of blocking S5{alpha}RI and S5{alpha}RII formation of dihydrotestosterone. Prostate cancer patients receiving LY320236, a competitive inhibitor of 5{alpha}-reductase I and II, showed increased circulating estradiol levels with simultaneous reduction of serum PSA (44). Raloxifene, a selective estrogen receptor modulator, has been reported to increase apoptosis in recurrent prostate cancer cell lines DU145, PC3 (45) and the synthetic estrogen, diethylstilbestrol, decreased PSA levels in men with recurrent prostate cancer in a phase II clinical trials (46). Additionally, cytochrome P450 hydroxylation of estradiol to A-ring catechols can mediate cellular damage by redox cycling (47) and catechol phase II metabolite, 2-methoxyestradiol, has potent apoptotic and antiangiogenic effects (48).



View larger version (7K):
[in this window]
[in a new window]
  		Fig. 3. Biosynthesis of androgens and estrogens from adrenal precursor androstenedione. Double arrows, reversible enzyme reactions; single arrows, irreversible reactions. S5{alpha}RI/II, cytochrome P450 19A1 (Aromatase), and 17ß-hydroxysteroid dehydrogenase (17ß-HSD).

 
We characterized S5{alpha}RI and S5{alpha}RII expression in recurrent prostate cancer using immunohistochemistry and immunoblot analysis and enzyme activity using in vitro assays. These data suggest that inhibition of both S5{alpha}RI and S5{alpha}RII may offer effective treatment for recurrent prostate cancer. Although finasteride, a selective S5{alpha}RII mechanism–based inhibitor and flutamide, an antiandrogen, have been shown to be an effective therapy for prostate cancer (49), finasteride is ineffective in recurrent prostate cancer (18). Dutasteride has been used safely to treat men with lower urinary tract symptoms (50) and LY320236, an inhibitor of S5{alpha}RI and II, decreased serum PSA levels in a limited study of nine castrated men with prostate cancer (44). Dutasteride, a dual S5{alpha}RI and II inhibitor, may decrease tissue dihydrotestosterone levels below those necessary for androgen receptor activation. Future characterization of androgen receptor–regulated gene expression after dutasteride treatment in prostate cancer cell lines or increased survival rates in clinical studies will support inhibition of both isozymes of S5{alpha}R. Dutasteride should be investigated to determine if it can extend the duration of remission induced by androgen deprivation therapy or induce re-remission of recurrent prostate cancer.


   Acknowledgments
 
We thank Dr. Catherine B. Lazier for 5{alpha}-reductase I and II antibodies and Dr. Frank S. French for comments and critical review of the manuscript.


   Footnotes
 
Grant support: National Cancer Institute grant CA-77739.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: C.W. Gregory is currently at Voyager Pharmaceutical Corporation, Raleigh, NC.

Received 4/15/04; revised 3/ 9/05; accepted 3/17/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113–8.[CrossRef][Medline]
  2. Hsing AW, Reichardt JKV, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213–35.[CrossRef][Medline]
  3. Balanger B, Balanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat, guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695–8.[CrossRef][Medline]
  4. Russell DW, Wilson JD. Steroid 5{alpha}-reductase: two genes two enzymes. Annu Rev Biochem 1994;63:25–61.[Medline]
  5. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10–30.[Abstract/Free Full Text]
  6. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251–65.[CrossRef][Medline]
  7. Huggins CB, Stephens RC, Hodges CV. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209–12.
  8. De Vere White R, Meyers F, Chi SG, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997;31:1–6.
  9. Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998;35:63–70.[CrossRef][Medline]
  10. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–8.[Abstract/Free Full Text]
  11. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718–24.[Abstract/Free Full Text]
  12. Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systemic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718–23.[CrossRef][Medline]
  13. Visakorpi T, Hytinen E, Koivist P, et al. In vivo amplification of the androgen receptor gene in progression of human prostate cancer. Nat Genet 1995;9:401–6.[CrossRef][Medline]
  14. Culig Z, Hobisch A, Bartsch G, Klocker H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc Res Tech 2000;51:447–55.[CrossRef][Medline]
  15. Tan J-A, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptor expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450–9.[Abstract/Free Full Text]
  16. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.[CrossRef][Medline]
  17. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61–73.[Abstract]
  18. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.[Abstract/Free Full Text]
  19. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315–9.[Abstract/Free Full Text]
  20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844–7.[CrossRef][Medline]
  21. Kim D, Gregory CW, Smith GJ, Mohler JL. Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 1999;35:2–10.[CrossRef][Medline]
  22. Thomas LN, Douglas RC, Vessey JP, et al. 5{alpha}-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019–25.[CrossRef][Medline]
  23. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293–7.[Medline]
  24. Miyamoto KK, McSherry SA, Dent GA, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015–9.[Medline]
  25. Moore RJ, Wilson JD. Reduced nicotinamide adenine dinucleotide phosphate: {delta}-4-3-ketosteroid 5{alpha}-oxidoreductase. Methods Enzymol 1975;36:466–74.[Medline]
  26. Lowry OH, Rosebrough NJ, Farr AL, Randell RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75.[Free Full Text]
  27. Steckelbroeck S, Watzka M, Reichelt R, et al. Characterization of the 5{alpha}-reductase-3-hydroxysteroid dehydrogenase complex in the human brain. J Clin Endocrinol Metab 2001;86:1324–31.[Abstract/Free Full Text]
  28. Aumuller G, Eicheler W, Renneberg H, Adermann K, Vilja P, Forssman WG. Immunocytochemical evidence for differential subcellular localization of 5{alpha}-reductase isoenzymes in human tissues. Acta Anat (Basel) 1996;156:241–52.[Medline]
  29. Bonkhoff H, Stein U, Aumuller G, Remberger K. Differential expression of 5{alpha}-reductase isoenzymes in human prostate and prostatic carcinomas. Prostate 1996;29:261–7.[CrossRef][Medline]
  30. Brendler CB, Follansbee AL, Isaacs JT. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. J Urol 1985;133:495–501.[Medline]
  31. Shirakawa T, Okada H, Acharya B, et al. Messenger RNA levels and enzyme activities of 5{alpha}-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 2004;58:33–40.[CrossRef][Medline]
  32. Soderstrom TG, Bjelfman C, Brekkan E, et al. Messenger ribonucleic acid levels of steroid 5{alpha}-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001;86:855–8.[Abstract/Free Full Text]
  33. Pratis K, O'Donnell L, Ooi GT, McLachlan RI, Robertson DM. Enzyme assay for 5{alpha}-reductase type 2 activity in the presence of 5{alpha}-reductase type I activity in rat testis. J Steroid Biochem Mol Biol 2000;75:75–82.[CrossRef][Medline]
  34. Weingartner K, Ben-Sasson SA, Stewart R, Richie JP, Riedmiller H, Folkman J. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 1998;159:465–70.[CrossRef][Medline]
  35. Salomao DR, Graham SD, Bostwick DB. Microvascularization invasion of prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119:1050–4.[Medline]
  36. Mabjeesh NJ, Willard MT, Frederickson CE, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416–25.[Abstract/Free Full Text]
  37. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1{alpha} in common human cancers and their metastases. Cancer Res 1999;59:5830–5.[Abstract/Free Full Text]
  38. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075–83.[Abstract/Free Full Text]
  39. Kaluzova M, Kaluz S, Stanbridge EJ. High cell density induces expression from the carbonic anhydrase 9 promoter. Biotechniques 2004;36:228–34.[Medline]
  40. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996;14:176–86.[CrossRef][Medline]
  41. Jin Y, Penning TM. Steroid 5-reductases and 3-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 2001;15:79–94.[CrossRef][Medline]
  42. Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997;31:118–24.[CrossRef][Medline]
  43. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972;34:730–5.[Medline]
  44. Eisenberger MA, Laufer M, Vogelzang NJ, et al. Phase I and clinical pharmacology of a type I and II, 5-{alpha}-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology 2004;63:114–9.[Medline]
  45. Kim IY, Kim B-C, Seong DH, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002;62:5365–9.[Abstract/Free Full Text]
  46. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstielbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257–60.[CrossRef][Medline]
  47. Liehr JG. Genotoxic effects of estrogens. Mutat Res 1990;238:269–76.[Medline]
  48. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165–72.[CrossRef][Medline]
  49. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995;154:1642–6.[Medline]
  50. Roehrborn CG, Boyle J, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-{alpha}-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. Fromont, M. Yacoub, A. Valeri, P. Mangin, G. Vallancien, G. Cancel-Tassin, and O. Cussenot
Differential Expression of Genes Related to Androgen and Estrogen Metabolism in Hereditary versus Sporadic Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1505 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Montgomery, E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
Cancer Res., June 1, 2008; 68(11): 4447 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K Wako, T Kawasaki, K Yamana, K Suzuki, S Jiang, H Umezu, T Nishiyama, K Takahashi, T Hamakubo, T Kodama, et al.
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
J. Clin. Pathol., April 1, 2008; 61(4): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. P. Mahajan, Y. Liu, S. Majumder, M. R. Warren, C. E. Parker, J. L. Mohler, H. S. Earp, and Y. E. Whang
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
PNAS, May 15, 2007; 104(20): 8438 - 8443.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Xu, S. L. Dalrymple, R. E. Becker, S. R. Denmeade, and J. T. Isaacs
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers.
Clin. Cancer Res., July 1, 2006; 12(13): 4072 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Cancer Res., March 1, 2006; 66(5): 2815 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. R. Bauman, S. Steckelbroeck, M. V. Williams, D. M. Peehl, and T. M. Penning
Identification of the Major Oxidative 3{alpha}-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5{alpha}-Androstane-3{alpha},17{beta}-diol to 5{alpha}-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease
Mol. Endocrinol., February 1, 2006; 20(2): 444 - 458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Titus, M. J. Schell, F. B. Lih, K. B. Tomer, and J. L. Mohler
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4653 - 4657.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Titus, M. A.
Right arrow Articles by Mohler, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Titus, M. A.
Right arrow Articles by Mohler, J. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online